Inclusion Criteria:  Symptomatic, severe aortic stenosis Eligible for delivery of the DurAVR™ THV Anatomy appropriate to accommodate safe placement of DurAVR™ THV Understands the study requirements and the treatment procedures and provides written informed consent. Subject agrees to complete all required scheduled follow-up visits.  Exclusion Criteria:  Anatomical  Anatomy precluding safe placement of DurAVR™ THV Pre-existing prosthetic heart valve in any position Unicuspid or bicuspid aortic valve Severe aortic regurgitation Severe mitral or severe tricuspid regurgitation requiring intervention Moderate to severe mitral stenosis Hypertrophic obstructive cardiomyopathy Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment Severe basal septal hypertrophy with outflow gradient Clinical Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment Determined inoperable/ineligible for surgery by the Heart Team Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure Blood dyscrasias as defined: leukopenia (WBC < 1000mm3), thrombocytopenia (platelet count < 50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support Need for emergency surgery for any reason Ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 40% as measured by resting echocardiogram Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA) Symptomatic carotid or vertebral artery disease End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min GI bleeding within the past 3 months A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, nitinol (titanium or nickel), ticlopidine and clopidogrel, contrast media Ongoing sepsis, including active endocarditis Subject refuses a blood transfusion Life expectancy < 12 months due to associated non-cardiac co-morbid conditions Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits) Currently participating in an investigational drug or another investigational device trial Subject belongs to a vulnerable population.